Ubs Asset Management Americas Inc Argenx Se Transaction History

Ubs Asset Management Americas Inc

$477 Billion
Q2 2025

A detailed history of Ubs Asset Management Americas Inc transactions in Argenx Se stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 24,419 shares of ARGX stock, worth $19.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

24,419

Previous 570 4184.04%

Holding current value

$19.2 Million

Previous $337,000 3894.07%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$532.27 - $656.65 $12.7 Million - $15.7 Million	23,849 Added 4184.04%	24,419 $13.5 Million
Q1 2025 May 19, 2025	SELL	$571.0 - $671.75 $11.3 Million - $13.3 Million	-19,855 Reduced 97.21%	570 $337,000
Q4 2024 Feb 14, 2025	SELL	$520.52 - $638.33 $10.6 Million - $13 Million	-20,417 Reduced 49.99%	20,425 $12.6 Million
Q3 2024 Nov 14, 2024	BUY	$434.22 - $551.9 $17.3 Million - $22 Million	39,923 Added 4344.18%	40,842 $22.2 Million
Q2 2024 Aug 13, 2024	SELL	$356.01 - $451.55 $15.2 Million - $19.3 Million	-42,731 Reduced 97.89%	919 $395,000
Q1 2024 May 15, 2024	BUY	$356.95 - $413.29 $1.85 Million - $2.14 Million	5,190 Added 13.49%	43,650 $17.2 Million
Q4 2023 Feb 14, 2024	BUY	$338.91 - $506.01 $2.55 Million - $3.81 Million	7,526 Added 24.33%	38,460 $14.6 Million
Q3 2023 Nov 13, 2023	SELL	$369.35 - $548.43 $1.31 Million - $1.94 Million	-3,545 Reduced 10.28%	30,934 $15.2 Million
Q1 2023 May 15, 2023	SELL	$334.23 - $403.65 $1.89 Million - $2.29 Million	-5,664 Reduced 14.11%	34,479 $12.8 Million
Q4 2022 Feb 14, 2023	BUY	$342.17 - $402.31 $29,768 - $35,000	87 Added 0.22%	40,143 $15.2 Million
Q3 2022 Nov 14, 2022	SELL	$343.2 - $395.75 $2.07 Million - $2.39 Million	-6,027 Reduced 13.08%	40,056 $14.1 Million
Q2 2022 Aug 12, 2022	SELL	$269.58 - $378.88 $1.45 Million - $2.03 Million	-5,371 Reduced 10.44%	46,083 $17.5 Million
Q1 2022 May 16, 2022	BUY	$254.45 - $351.06 $547,067 - $754,779	2,150 Added 4.36%	51,454 $16.2 Million
Q4 2021 Feb 14, 2022	SELL	$272.01 - $353.03 $889,200 - $1.15 Million	-3,269 Reduced 6.22%	49,304 $17.3 Million
Q3 2021 Nov 15, 2021	SELL	$295.0 - $350.58 $523,625 - $622,279	-1,775 Reduced 3.27%	52,573 $15.9 Million
Q2 2021 Aug 16, 2021	BUY	$257.11 - $319.92 $278,450 - $346,473	1,083 Added 2.03%	54,348 $16.4 Million
Q1 2021 May 14, 2021	SELL	$268.3 - $380.31 $4.52 Million - $6.4 Million	-16,831 Reduced 24.01%	53,265 $14.7 Million
Q4 2020 Mar 01, 2021	BUY	$248.13 - $308.36 $5.4 Million - $6.71 Million	21,761 Added 45.02%	70,096 $20.6 Million
Q3 2020 Nov 13, 2020	SELL	$215.51 - $272.51 $1.22 Million - $1.54 Million	-5,653 Reduced 10.47%	48,335 $12.7 Million
Q2 2020 Aug 14, 2020	SELL	$127.44 - $232.72 $3.63 Million - $6.63 Million	-28,488 Reduced 34.54%	53,988 $12.2 Million
Q1 2020 May 15, 2020	SELL	$108.83 - $165.23 $1.32 Million - $2.01 Million	-12,135 Reduced 12.83%	82,476 $10.9 Million
Q4 2019 Feb 14, 2020	SELL	$106.59 - $164.21 $26,114 - $40,231	-245 Reduced 0.26%	94,611 $15.2 Million
Q3 2019 Nov 14, 2019	SELL	$113.31 - $150.51 $2.33 Million - $3.09 Million	-20,520 Reduced 17.79%	94,856 $10.8 Million
Q2 2019 Aug 15, 2019	SELL	$115.0 - $141.58 $281,290 - $346,304	-2,446 Reduced 2.08%	115,376 $0
Q1 2019 May 14, 2019	BUY	$98.85 - $134.59 $4.72 Million - $6.43 Million	47,772 Added 68.2%	117,822 $0
Q4 2018 Feb 13, 2019	SELL	$63.81 - $109.82 $60,619 - $104,329	-950 Reduced 1.34%	70,050 $6.73 Million
Q3 2018 Nov 14, 2018	BUY	$75.5 - $96.63 $5.36 Million - $6.86 Million	71,000 New	71,000 $0

Others Institutions Holding ARGX

# of Institutions

491

Shares Held

28.3M

Call Options Held

370K

Put Options Held

211K

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $43.6B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Argenx Se Transaction History